QLC7401

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

TicsHypercholesterolemiaFamilial Hypercholesterolemia

114 competitors in Tics

#DrugCompanyPhaseTrials

1

Sodium Valproate

AstraZeneca

Phase 3

12

Priftin

Sanofi

Phase 2

13

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

44

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 1

545

Duvyzat

Italfarmaco

Phase 2

26

Dilaudid

RRhodes Pharmaceuticals, L.P.

Phase 2

17

CAB LA

GSK

Phase 2

18

Aciphex

Akero Therapeutics

Phase 1

99

Invokana

WWim Janssens

Phase 1

810

QLC7401

Qilu Pharmaceutical Co., Ltd.

Phase 3

1Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hypercholesterolemia2 trials

QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Not yet recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07441317·780 enrolled

Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

Not yet recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06750341·156 enrolled

Familial Hypercholesterolemia2 trials

QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Not yet recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07450378·120 enrolled

QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

Not yet recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07444086·510 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics Study

Not yet recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT07074236·48 enrolled

Details

Drug Info

Related News